Patients diagnosed with iris, ciliary body or choroidal melanoma of high-risk tumour cytogenetics (monosomy 3>/= 20% of cells), were treated with adjuvant low-dose dacarbacine (DTIC) and interferon –alpha-2b (IFNA-2b), following primary treatment (enucleation, brachytherapy or resection). DTIC was given intravenously...